Search Results - Makh, Shavy

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

    Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE by Perumal, Jai, Fox, Robert J, Balabanov, Roumen, Balcer, Laura J, Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, Lily

    Published in BMC neurology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

    Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 by Brys, Miroslaw, Fanning, Laura, Hung, Serena, Ellenbogen, Aaron, Penner, Natalia, Yang, Minhua, Welch, Mackenzie, Koenig, Erica, David, Eric, Fox, Tara, Makh, Shavy, Aldred, Jason, Goodman, Ira, Pepinsky, Blake, Liu, YuTing, Graham, Danielle, Weihofen, Andreas, Cedarbaum, Jesse M.

    Published in Movement disorders
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: